A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies Meeting Abstract
| Authors: | McKay, R. R.; Werner, L.; Harshman, L. C.; Bellmunt, J.; Sweeney, C.; Rosenberg, J. E.; VanAllen, E.; Walsh, M. K.; Vaishampayan, U. N.; McDermott, D. F.; Choueiri, T. K. |
| Abstract Title: | A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901030 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.4559 |
| Notes: | Meeting Abstract: 4559 -- Source: Wos |
